https://doi.org/10.4081/cdr.12.12626
Exfoliated dermatitis and hepatitis to first line anti-tubercular therapy with treatment of drug-sensitive tuberculosis with second line anti-tubercular therapy: a roller coaster ride
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 3 June 2024
The Adverse Drug Reactions (ADRSs) to Anti-Tubercular Therapy (ATT) have been reported from 8% to 85% worldwide, while the prevalence of ADRSs to 1st line ATT from India reported 2.3% to 17%, with more during the intensive phase and daily regime. However, cutaneous ADRSs related to ATT are less commonly seen. Common cutaneous ADRSs are maculopapular rash, urticarial, erythema multiforme, exfoliative dermatitis, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Among the 1st line ATT, pyrazinamide is the most common cause at 2.38%, and isoniazid is reported the least at 0.98%. Exfoliated dermatitis is rarely seen with 1st line ATT therapy limited to some case reports and case series.
Downloads
Singh A, Prasad R, Balasubramanian V, et al. Prevalence of adverse drug reaction with first-line drugs among patients treated for pulmonary tuberculosis. Clin Epidemiol Glob Health 2015;3:S80-90. DOI: https://doi.org/10.1016/j.cegh.2015.10.005
Sharma RK, Verma GK, Tegta GR, et al. Spectrum of cutaneous adverse drug reactions to antitubercular drugs and safe therapy after rechallenge - A retrospective study. Indian Dermatol Online J 2020;11:177-81. DOI: https://doi.org/10.4103/idoj.IDOJ_133_19
Varghese AM, Kandra N, Uppala PK, et al. Anti-Tubercular Therapy (ATT) induced exfoliative dermatitis A case series. Indian J Tuberc 2023;70:253-7. DOI: https://doi.org/10.1016/j.ijtb.2022.08.001
Dua R, Sindhwani G, Rawat J. Exfoliative dermatitis to all four first line oral anti-tubercular drugs. Indian J Tuberc 2010;57:53-6.
World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-susceptible tuberculosis treatment. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK581329/
Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-87. DOI: https://doi.org/10.1056/NEJMoa1407426
Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014;371:1588-98. DOI: https://doi.org/10.1056/NEJMoa1315817
Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014;371:1599-608. DOI: https://doi.org/10.1056/NEJMoa1314210
Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med 2022;386:911-22. DOI: https://doi.org/10.1056/NEJMoa2104535
Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 2021;384:1705-18. DOI: https://doi.org/10.1056/NEJMoa2033400
Mandal PK, Mandal A, Bhattacharyya SK. Comparing the daily versus the intermittent regimens of the antitubercular chemotherapy in the initial intensive phase in non-HIV, sputum positive, pulmonary tuberculosis patients. J Clin Diagn Res 2013;7:292-5.
Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. DOI: https://doi.org/10.1164/rccm.167.4.603
Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. N Engl J Med. 2023;388:873-87. DOI: https://doi.org/10.1056/NEJMoa2212537
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
